Safety and efficacy of twice daily administration of KPI-121 1% for ocular inflammation and pain following cataract surgery
Terry Kim,1 Kenneth Sall,2 Edward J Holland,3 R Kim Brazzell,4 Susan Coultas,4 Preeya K Gupta1 1Department of Ophthalmology, Duke University Eye Center, Durham, NC, USA; 2Sall Research Medical Center, Inc, Artesia, CA, USA; 3Department of Ophthalmology, Cincinnati Eye Institute, University of Cinci...
Main Authors: | Kim T, Sall K, Holland EJ, Brazzell RK, Coultas S, Gupta PK |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2018-12-01
|
Series: | Clinical Ophthalmology |
Subjects: | |
Online Access: | https://www.dovepress.com/safety-and-efficacy-of-twice-daily-administration-of-kpi-121-1-for-ocu-peer-reviewed-article-OPTH |
Similar Items
-
Loteprednol etabonate (submicron) ophthalmic gel 0.38% dosed three times daily following cataract surgery: integrated analysis of two Phase III clinical studies
by: Fong R, et al.
Published: (2019-08-01) -
Formulation and evaluation of in situ ophthalmic gel of loteprednol etabonate
by: Shaikh Shoaeba, et al.
Published: (2021-06-01) -
A retrospective analysis of the use of loteprednol etabonate ophthalmic suspension 0.5% following canaloplasty
by: Khaimi MA
Published: (2018-02-01) -
Managing Dry Eye Disease with Novel Medications: Mechanism, Study Validity, Safety, Efficacy, and Practical Application
by: Jason C. Wong, et al.
Published: (2024-01-01) -
Efficacy, Safety and Steroid-sparing Effect of Topical Cyclosporine A 0.05% for Vernal Keratoconjunctivitis in Indian Children
by: Arkendu Chatterjee, et al.
Published: (2019-10-01)